Compare · DXCM vs NMTC
DXCM vs NMTC
Side-by-side comparison of DexCom Inc. (DXCM) and NeuroOne Medical Technologies Corporation (NMTC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and NMTC operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $31.90B, about 2072.8x NMTC ($15.4M).
- Over the past year, DXCM is up 7.7% and NMTC is down 68.2% - DXCM leads by 75.9 points.
- DXCM has been more active in the news (8 items in the past 4 weeks vs 7 for NMTC).
- DXCM has more recent analyst coverage (25 ratings vs 4 for NMTC).
- Company
- DexCom Inc.
- NeuroOne Medical Technologies Corporation
- Price
- $84.49-3.84%
- $1.71+2.71%
- Market cap
- $31.90B
- $15.4M
- 1M return
- -0.34%
- +7.91%
- 1Y return
- +7.73%
- -68.20%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- News (4w)
- 8
- 7
- Recent ratings
- 25
- 4
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
NeuroOne Medical Technologies Corporation
NeuroOne Medical Technologies Corporation operates as a medical technology company. It focuses on the development and commercialization of thin film electrode technology for continuous electroencephalogram (cEEG) and stereoelectroencephalography (sEEG) recording, spinal cord stimulation, brain stimulation, and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, and other related brain related disorders. NeuroOne Medical Technologies Corporation has a strategic partnership with RBC Medical Innovations to develop and manufacture a radiofrequency generator for use with NeuroOne's combination recording and ablation electrode to record brain activity and ablate brain tissue using the same electrode. The company is based in Eden Prairie, Minnesota.
Latest DXCM
- Dexcom Announces Upcoming Conference Presentation
- EVP Chief People & Culture Off Stern Sadie sold $226,669 worth of shares (2,565 units at $88.37) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 126,043 units (SEC Form 4)
- EVP Chief Legal Compliance Off Brown Michael Jon covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 1% to 101,502 units (SEC Form 4) (withholding obligation)
- EVP, Chief Financal Officer Sylvain Jereme M covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 0.96% to 150,390 units (SEC Form 4) (withholding tax)
- President, CEO, and Director Leach Jacob Steven covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 0.35% to 418,908 units (SEC Form 4) to satisfy withholding tax
- EVP Chief People & Culture Off Stern Sadie covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 1% to 128,608 units (SEC Form 4) (withholding tax)
- Executive Chair Sayer Kevin R sold $2,408,242 worth of shares (26,756 units at $90.01) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 302,214 units (SEC Form 4)
- EVP Chief Legal Compliance Off Brown Michael Jon sold $156,281 worth of shares (1,700 units at $91.93) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 102,953 units (SEC Form 4)
- Director Augustinos Nicholas gifted 1,075 shares (SEC Form 4)
- Director Heller Bridgette P sold $89,349 worth of shares (1,012 units at $88.29) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 29,570 units (SEC Form 4)
Latest NMTC
- Chief Business Officer Wambeke David J. bought $66,999 worth of shares (33,333 units at $2.01), increasing direct ownership by 20% to 199,999 units (SEC Form 4)
- SEC Form 4 filed by Chief Administrative Officer Johns Emily J.
- SEC Form 4 filed by Chief Financial Officer Volker Christopher
- SEC Form 4 filed by Market Development Director Christianson Mark
- SEC Form 4 filed by Chief Technology Officer Mertens Steve
- SEC Form 4 filed by CEO & President Rosa David A
- NeuroOne Medical Technologies Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form 10-Q filed by NeuroOne Medical Technologies Corporation
- NeuroOne Medical Technologies Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Amendment: SEC Form SCHEDULE 13G/A filed by NeuroOne Medical Technologies Corporation